Key result
OCE-205 shows favorable safety and predictably raises mean arterial pressure in healthy volunteers.
Why the study?
OCE-205 is a novel selective vasopressin V1a receptor mixed agonist-antagonist that may improve treatment of portal hypertension-related complications in end-stage liver disease compared to current nonselective full-agonist vasopressin analogs.
RCT (n=64)
Double-blind
Computer-generated randomization list
No
Answers are grounded in this paper and cite their sources.
Supports advancement to patient trials; extends Phase 1 safety, PK, and PD data for partial V1a agonism.
BACKGROUND: OCE-205, a novel, selective vasopressin V1a receptor mixed agonist/antagonist with no V2 receptor activity, may treat the portal hypertension-related complications of end-stage liver disease with an improved therapeutic profile over currently utilized nonselective full-agonist vasopressin analogs. OBJECTIVES: This Phase 1, double-blind, placebo-controlled, within-dose-group randomized trial investigated the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of OCE-205 in healthy adults. METHODS: Subjects received a single intravenous dose of OCE-205 0.1, 0.3, 0.45, 0.6, or 0.9 mg, or placebo infused over 6 h. Safety and tolerability were assessed, and blood samples were obtained for pharmacokinetic analyses. Sixty-four subjects were randomized and treated. RESULTS: ) were approximately dose-proportional across doses from 0.1 to 0.9 mg. OCE-205 terminal half-life was ~ 1.5 h. Diastolic, and to a lesser extent systolic, blood pressure increased in all OCE-205 dose groups; pulse rate decreased. Overall changes in mean arterial pressure were similar to changes in diastolic blood pressure. Absolute changes in cardiac output, by echocardiogram, were somewhat dose-dependent, with mean reductions of 3-12% after the 0.9 mg dose, and individual reductions ≤ 20 to 25% across all doses. The most frequent adverse events were abdominal pain, abnormal gastrointestinal sounds, and diarrhea, with no reported cases of mesenteric ischemia. Adverse events were generally mild or moderate in severity. CONCLUSION: OCE-205 was safe and well tolerated, with a pharmacodynamic profile achieving submaximal partial agonism consistent with mixed agonism-antagonism of the V1a receptor. OCE-205 shows promise as a treatment for some complications of end-stage liver disease.
No takes yet. Share an insight, caveat, or question.
Bagger et al. (2023) conducted an RCT in Healthy volunteers (n=64). OCE-205 vs. Placebo was evaluated on Safety, tolerability, and pharmacokinetic/pharmacodynamic profiles. OCE-205 was safe and well tolerated in healthy volunteers, exhibiting dose-proportional pharmacokinetics and expected submaximal partial V1a receptor agonism with predictable increases in mean arterial pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: